NLRP3 and metabolic dysfunction-associated steatohepatitis: Consistent with these findings, a previous study showed that the mRNA levels of NLRP3 in the livers of patients with non-alcoholic fatty liver disease (NAFLD), were significantly higher in the livers of patients with non-alcoholic steatohepatitis (NASH) when compared to the livers of patients with non-NASH19.